Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RH109 Booster in Healthy Adults
NCT05609045Phase 1Withdrawn
- Sponsor
- Rhegen Bio
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Prophylactic Vaccines, mRNA Therapeutics
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing RH109 Group with Placebo Group (2 arms). Primary endpoints: Reactogenicity, Unsolicited Treatment Emergent Adverse Events and 1 more. Planned start Jun 2023; status: withdrawn.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05609045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609045.